Advanced 3-D Imaging Technique Used for First Time to View IPF in Lung Tissues

Advanced 3-D Imaging Technique Used for First Time to View IPF in Lung Tissues

Researchers at the University of Southampton used an advanced, 3-D X-ray imaging technology for a first time on lung tissue samples from idiopathic pulmonary fibrosis (IPF) patients, gaining a better understanding of how the aggressive lung disease develops in the body. The study, “Three-dimensional characterization of fibroblast foci in idiopathic pulmonary fibrosis” was published…

Karos’ Experimental Therapy for PAH and Fibrotic Diseases, KAR5585, Advances in Phase 1 Study

Karos Pharmaceuticals recently announced that its small molecule drug candidate, KAR5585, has advanced in Phase 1 clinical testing. The drug is being developed for the treatment of pulmonary arterial hypertension (PAH) and other diseases characterized by extensive fibrosis. KAR5585 received Orphan Drug designation for the treatment of PAH by the U.S. Food and Drug Administration…

Factor That Prevent Blood Clots, Thrombomodu­lin, Seen to Reduce Mortality in IPF Patients After Flares

Japanese researchers reported that treatment with thrombomodu­lin, an anti-clotting factor naturally produced in the body, reduced mortality in patients experiencing acute exacerbations of idiopathic pulmonary fibrosis (IPF). The findings also suggested that abnormal blood clotting may contribute to poor outcomes following these flares. Thrombomodu­lin is a factor crucial for controlling the blood-clotting…

6 Pulmonary Fibrosis Complications

There is currently no cure for pulmonary fibrosis and patients often face a prognosis of three to five years after diagnosis. However, medication and other treatment options can help improve patients’ quality of life. But as the disease evolves, there are some complications that…